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Abstract 
Background: There is a paucity of data on the current management of patients with advanced soft tissue sarcoma 
(STS) in the Australian health care setting. This study utilised the Australian sarcoma database to evaluate the patterns 
of care delivered to patients with advanced STS at Australian sarcoma services.
Methods: Prospectively collected data from six sarcoma centres in Australia were sourced to identify patients 
diagnosed with advanced STS between 1 January 2010 and 31 December 2012. Descriptive statistics were analysed 
for patient demographics, clinicopathological characteristics and treatment patterns. Overall survival was estimated 
using the Kaplan–Meier product limit method.
Results: Of 253 patients with advanced STS, four major STS subtypes were identified: undifferentiated pleomorphic 
sarcoma (23 %), leiomyosarcoma (17 %), liposarcoma (14 %), and synovial sarcoma (8 %); with the rest grouped as 
“other STS” (38 %). Approximately one‑third of patients received palliative systemic therapy with the most common 
first‑line therapy being doxorubicin alone (50 %). A small percentage of patients participated in clinical trials (20 %). 
Palliative radiotherapy was utilised mostly for treatment of symptomatic distant metastases and one‑third of patients 
underwent metastasectomy, most commonly for pulmonary metastases. The median overall survival (OS) in this series 
was 18 months and no significant difference in OS was observed across different STS histological subtypes.
Conclusions: This is the first detailed study outlining patterns of care for Australian patients with advanced STS man‑
aged at sarcoma services. These data highlight a particular area of weakness in the lack of clinical trials for sarcoma 
patients and also serve as an important reference point for understanding how practice may change over time as 
treatment options evolve.
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Background
Soft tissue sarcomas (STS) comprise a heterogeneous 
group of diseases, accounting for less than 1  % of adult 
malignancies [1]. Metastatic or locally advanced STS is 
generally considered incurable with the mainstay of treat-
ment being systemic chemotherapy. For some patients 
with limited disease burden however, long-term remis-
sion can be achieved through a multimodality approach 
involving medical, surgical and radiation therapy. The 
goal of treatment here is to prolong survival whilst main-
taining or improving quality of life and dealing with spe-
cific disease-related symptoms.
In clinical practice, the decision-making process 
regarding the choice of systemic therapy, the tim-
ing of treatment and the use of single versus com-
bination therapy is highly complex. International 
guidelines such as the National Comprehensive 
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Cancer Network and the European Society of Medi-
cal Oncology offer some consensus on the first-line 
treatment with anthracycline-based therapy [2, 3]. 
However, systemic therapy options remain lim-
ited beyond the first- and second-line therapy with 
a lack of evidence for improvement in overall sur-
vival with anthracycline-containing doublet chemo-
therapy [4–7]. Newer agents such as trabectedin 
and pazopanib with promising activity for certain 
histologic subtypes have been identified, but these 
remain a minority and access continues to be a chal-
lenge for the treating team and their patients. As 
novel agents are developed and approved by the 
regulatory authority, access is highly variable across 
geographical regions around the globe. Ostensibly 
these differences in access to effective drugs influ-
ence treatment choice but little is known about how 
treatment algorithms are modified accordingly in 
routine clinical practice.
A recent study by the North American and European 
colleagues described chemotherapy treatment patterns 
and clinical outcomes for patients with metastatic STS 
highlighting the poor overall survival for this group and 
the need for more therapeutic options [8]. There is a pau-
city of data on the current practice of managing patients 
with advanced STS in the Australian health care setting. 
The primary goal of this study was to utilise the Austral-
ian sarcoma database to evaluate the current patterns of 
care for patients with advanced STS, managed at sarcoma 
specialist centres.
Methods
A customised electronic database capturing clinical 
data considered most relevant to bone and soft tissue 
sarcomas were established at major sarcoma centres 
around Australia, with data collection commencing in 
2009, approved by the governing ethics committee at 
each institution. Data from six sarcoma centres were 
sourced to identify patients diagnosed with advanced 
STS between 1st January 2010 and 31st December 
2012, with a minimum follow up period of 12 months. 
Subjects aged 18 and above with locally advanced and/
or metastatic STS were selected for inclusion into the 
study if they received care at sarcoma specialist centres 
with at least two visits during the study period. Data on 
all systemic therapies given with palliative-intent were 
collated. Information on palliative therapy other than 
systemic therapy, i.e. radiotherapy and/or surgery, was 
available in 89 % of the total study population (n = 225) 
for analysis. The BioGrid Australia platform was utilised 
to link the datasets for analysis. The study was approved 
by the Human Research Ethics Committee at Mel-
bourne Health.
Definitions
  • Advanced STS
We defined patients with advanced STS as patients 
with metastatic and/or locally advanced, unresectable 
histologically confirmed STS demonstrated by appropri-
ate imaging and biopsy. For the purpose of this study, we 
excluded patients with gastrointestinal stromal tumour, 
bone sarcomas, dermatofibrosarcoma protuberans, or 
rhabdomyosarcomas. (Table 1)
•  Palliative treatment modalities
We defined systemic chemotherapy, radiotherapy and 
surgery as palliative treatment modalities when they were 
used for the purpose of disease and symptom control in 
patients with advanced STS.
Statistical methods
Descriptive statistics were analysed for patients’ demo-
graphics, clinicopathological characteristics and treat-
ment patterns. Overall survival (OS) was estimated for 
the whole patient cohort using the Kaplan–Meier prod-
uct limit method and separately for different STS sub-
groups. The prognostic impact of these variables was 
explored via the log-rank test. Statistical calculations 
were performed using SAS Enterprise Guide 6.1 (SAS 
institute Inc, Cary, NC, USA).
Results
A total of 942 individuals were identified as having his-
tologically confirmed STS diagnosed between 1st Janu-
ary 2010 and 31st December 2012, of which 253 (27 %) 
were considered as having advanced STS. Of this group, 
34 % (n =  86) had metastatic disease at diagnosis, with 
the remainder presenting with local recurrence that was 
unresectable and/or distant metastatic disease. The mean 
Table 1 Soft tissue sarcoma WHO classification subtypes 
included and excluded in the study
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age at diagnosis was 59 years (range; 18–95). There was 
a slight male preponderance with 149 males and 104 
females represented in the cohort. The most frequent pri-
mary tumour sites were extremity (45 %), followed by ret-
roperitoneum (15 %), intra-abdominal and intra-thoracic 
(11 % each). The lung was the most common site of dis-
tant metastasis (66 %), followed by intra-abdomen (28 %) 
and bone (19 %).
Based on tumour histology, the study cohort (n = 253) 
was classified into four major STS subtypes: undifferen-
tiated pleomorphic sarcoma (n = 57; 23 %), leiomyosar-
coma (n = 44; 17 %), liposarcoma (n = 34; 14 %), synovial 
sarcoma (n =  21; 8  %); with the rest grouped as “other 
STS” (n = 97; 38 %); consisting of 15 histologic subtypes, 
each with small sample sizes. The uptake of palliative-
intent systemic therapy differed across the STS histologi-
cal subtypes with patients with synovial sarcomas most 
likely to be treated with systemic therapy compared to 
other subtypes (Table 2).
Palliative treatment modalities
Palliative treatment other than conventional cytotoxic 
chemotherapy was reviewed in those with available data 
(n = 225). A total of 86 patients (34 %) were treated with 
systemic therapies for advanced STS. More than a third 
of patients underwent radiotherapy or metastasectomy 
for palliation (37 %; radiotherapy, 35 %; surgery).
Approximately 75  % of all patients diagnosed with 
advanced STS received at least one line of palliative-
intent treatment modality. Fifty-five patients (22  %) 
underwent two or more lines of different modalities of 
treatment during their course of disease. There were 11 
patients (4  %) who received all three treatment modali-
ties. Those who were treated with systemic therapies 
tended to be younger (mean age 51 vs. 63 years) and were 
more likely to receive radiotherapy for palliation than 
those who were not treated with systemic therapies (49 
vs. 33 % respectively). There was a similar male to female 
ratio in each group.
Table 2 Demographics and clinical characteristics of patients with advanced STS
a Group treated with palliative-intent systemic therapy
b Group not treated with palliative-intent systemic therapy
c UPS; undifferentiated pleomorphic sarcoma
d This value dose not add up to 100 % due to some having multiple sites of distant disease at different time points
Characteristic Total (n = 253) Treated groupa (n = 86) Not treated groupb (n = 167) P
Age at diagnosis
Mean (range) 59 (18–91) 51 (18–85) 63 (22–95) N/A
Number of patients
<65 years, n (%) 147 (58) 68 (27) 79 (31) 0.0001
≥65 years, n (%) 106 (42) 18 (7) 88 (35)
Gender, n (%)
Female 104 (41) 37 (15) 67 (26) 0.687
Male 149 (59) 49 (19) 100 (40)
Stage IV at diagnosis 86 (34) 32 (13) 51 (20) 0.323
n (%)
Histological type, n (%)
UPSc 57 (23) 21 (8) 36 (14) N/A
Leiomyosarcoma 44 (17) 22 (9) 22 (9)
Liposarcoma 34 (14) 9 (4) 25 (10)
Synovial sarcoma 21 (8) 15 (6) 6 (2)
Other 97 (38) 19 (7) 78 (31)
Sites of metastases, n (%)d
Lung 167 (66) 78 (31) 89 (35) N/A
Intra‑abdominal 70 (28) 32 (13) 38 (15)
Bone 48 (19) 28 (11) 20 (8)
Lymph node 44 (17) 16 (6) 18 (7)
Head and neck 6 (2) 3 (1) 3 (1)
Other 27 (11) 10 (4) 17 (7)
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Systemic treatment patterns
Of the 86 patients who received palliative-intent sys-
temic therapy, 50 % (n = 43) received more than one line 
of systemic therapy (Table  3). In the first-line setting, 
the most common regimen used was doxorubicin alone 
(n  =  43, 55  %) followed by combination therapy with 
doxorubicin (or epirubicin in one patient) and ifosfamide 
(n =  14, 16 %). The majority of patients (n =  62, 72 %) 
received single-agent chemotherapy as the first-line ther-
apy. Patients receiving combination chemotherapy were 
younger than those receiving monotherapy (mean age, 46 
vs. 53 years respectively); with synovial sarcoma the most 
common subtype to receive doublet chemotherapy with 
doxorubicin and ifosfamide (n = 5, 38 %). Other doublet 
regimens used as the first-line therapy included the com-
bination of docetaxel and gemcitabine (n = 2), and that of 
gemcitabine and dacarbazine (n = 2). Fourteen patients 
(16  %) were enrolled in clinical trials for the first-line 
therapy. In the second-line setting, ifosfamide was the 
most frequently prescribed agent (n = 20, 53 %) with the 
majority of patients receiving it as monotherapy (n = 35, 
92 %) and with three additional patients participating in 
clinical trials. In the third-line setting, various regimens 
of monotherapy and combination therapies were pre-
scribed with dacarbazine, most commonly delivered as a 
single-agent (n = 7, 30 %). Newer systemic agents such as 
multi-targeted receptor tyrosine kinase inhibitor, pazo-
panib and marine alkaloid, trabectedin, were sporadically 
used as subsequent lines of therapy (pazopanib; n = 12, 
trabectedin; n = 3). Beyond the first-line treatment, the 
most commonly used combination regimen was gemcit-
abine and docetaxel. Eight patients were treated with oral 
cyclophosphamide at any given time period (first-line; 
n = 3, second-line; n = 1, third-line; n = 3, fourth-line; 
n = 1). No patients were enrolled in clinical trials beyond 
the second-line setting. Prior exposure to neoadjuvant or 
adjuvant chemotherapy (n = 41, 16 %) and STS histologi-
cal subtype did not affect the subsequent use of systemic 
therapy for advanced disease.
Other treatment patterns
Details of palliative-intent radiotherapy delivery and 
metastasectomy were available in 89  % of patients in 
this study (n  =  225). The majority of patients received 
palliative-intent radiotherapy for symptoms arising from 
distant metastases (n  =  81, 36  %), of which the most 
common sites included bone, followed by lung/medi-
astinum and intra-abdominal metastases. A further 
34  % of patients with advanced STS underwent resec-
tion of metastases, of which pulmonary metastasectomy 
was the most common procedure performed. Approxi-
mately 10  % of patients underwent more than one 
metastasectomies.
Survival analysis
There were 110 deaths captured in this series, accounting 
for 43 % of the patients with advanced STS in this study 
cohort. The median overall survival in this series was 
18 months (Fig. 1). Younger age at diagnosis of advanced 
STS (<65 years) conferred a statistically significant higher 
probability of survival than older age (≥65 years; log rank 
test p value 0.032). There was no statistically significant 
difference in overall survival stratified by STS histological 
Table 3 Summary of palliative systemic therapy in treated 
patients
a The percentage refers to the proportion of patients who received the 
corresponding line treatment out of the total number treated with systemic 
therapy (n = 86)
b One patient had epirubicin and ifosfamide
Systemic therapy line, n (%a) Treatment details
First‑line (n = 86, 100 %) Single‑agent chemtoherapy (n = 62, 
72 %)
Doxorubicin (n = 43)
Clinical trial (n = 7)
Ifosfamide (n = 4)
Paclitaxel (n = 3)
Other (n = 5)
Combination therapy (n = 24, 28 %)
Doxorubicinb and ifosfamide (n = 13)
Clinical trial (n = 7)
Other combination (n = 4)
Second‑line (n = 38, 44 %) Single‑agent chemtoherapy (n = 35, 
92 %)
Ifosfamide (n = 20)
Dacarbazine (n = 5)
Pazopanib (n = 3)
Clinical trial (n = 3)
Other (n = 4)
Combination therapy (n = 3, 8 %)
Third‑line (n = 20, 23 %) Single‑agent chemtoherapy (n = 18, 
90 %)
Pazopanib (n = 6)
Dacarbazine (n = 6)
Cyclophophamide (n = 3)
Other (n = 3)
Combination therapy (n = 2, 10 %)
Fourth‑line (n = 6, 7 %) Single‑agent chemtoherapy (n = 6, 
100 %)
Pazopanib (n = 2)
Doxorubicin (n = 1)
Ifosfamide (n = 1)
Cyclophophamide (n = 1)
Trabectedin (n = 1)
Fifth‑line (n = 1, 1 %) Pazopanib (n = 1)
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subtypes. In the subgroup of patients who had one or 
more lines of systemic therapy, the median overall sur-
vival was 11  months from the time of diagnosis with 
advanced STS.
Discussion
To our knowledge, this is the first detailed study outlining 
patterns of care for patients with advanced STS in Aus-
tralian sarcoma centres using a prospectively maintained 
sarcoma-specific database. The STS histological subtypes 
represented in this series were comparable to other stud-
ies on patients with STS [8, 9]. Although each subtype 
was small in number, the study findings provide valuable 
insights into how patients with advanced STS are rou-
tinely managed in real-world clinical practice. Consist-
ent with the literature, the most common site of distant 
metastasis was lung, and this was also reflected by a high 
uptake of pulmonary metastasectomy.
Over three quarters of all patients diagnosed with 
advanced STS received at least one modality of 
palliative-intent treatment. Systemic treatment, surgery 
and radiotherapy were used with almost equal distribu-
tion during the course of disease. A higher proportion 
of patients treated with systemic therapy also received 
palliative-intent radiotherapy than those who did not 
receive systemic therapy (49 vs. 33  %). The process 
involved in treatment decision-making is often complex 
and there may be several reasons for not recommend-
ing treatment for some patients with advanced STS. This 
may reflect the natural history of STS, which may exhibit 
more indolent course of disease with a lack of or mini-
mal symptoms requiring intervention. Soft tissue sarco-
mas are generally considered less responsive to systemic 
chemotherapy than bone sarcomas such as osteosarcoma 
or Ewing’s sarcoma. As a result, depending on the over-
all disease burden, it may be appropriate to delay starting 
chemotherapy until it is required. Patients’ performance 
status and comorbidities should also be weighed against 
potential treatment toxicities. Little is known about how 
these variables influence the treatment decision and the 
patients’ overall outcome. It would be valuable to explore 
these further in subsequent studies.
Therapeutic options for many solid tumours have rap-
idly expanded and evolved over the last decades, however, 
patients with STS continue to experience difficulties with 
limited therapeutic options. Traditionally, doxorubicin-
based regimens have been the standard of care [4–7, 10] 
and this was similarly observed in our practice with dox-
orubicin monotherapy or doxorubicin-containing combi-
nation chemotherapy as the most frequently prescribed 
first-line systemic therapy (n = 56, 65 %). In cases where 
other agents were administered, this was largely due to 
enrolment in clinical trials or the use of subtype-specific 
agents such as paclitaxel in angiosarcomas or gemcit-
abine and docetaxel in uterine leiomyosarcomas [11–13]. 
Interestingly, the uptake of doublet chemotherapy with 
gemcitabine and docetaxel was low at 7  % in Australia. 
This compares to approximately 30  % reported from 
the SABINE study and another single-institution North 
American study [8, 9]. This discrepancy may be related to 
differences in drug reimbursement available at the time 
of the study and a subsequent follow-up study will be 
of value to further characterise chemotherapy prescrib-
ing patterns impacted by changes in reimbursement over 
time. The uptake of doublet chemotherapy was also com-
monly seen, mostly in the younger patient groups with 
locally advanced STS. Given the evidence supporting the 
use of doxorubicin-based combination chemotherapy in 
improving the response rate at the expense of increased 
toxicities, this seems appropriate [2, 4–7].
It is well recognised that certain histological subtypes 
may have higher rates of chemo-sensitivity which may 
factor into the decision-making process for timing and 
a
b
Fig. 1 a Kaplan–Meier curves for overall survival. Overall survival for 
the whole patient cohort. b Kaplan–Meier curves for overall survivsl. 
Overall survival stratified by age group, <65 years versus ≥65 years
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type of treatment. Examples include ifosfamide with 
synovial sarcoma, taxanes with angiosarcoma and tra-
bectedin with myxoid/round cell liposarcomas [11, 12, 
14–16]. A closer review of treatment according to STS 
histological subtypes revealed a trend for an increased 
use of systemic therapy in patients with leiomyosarcoma 
and synovial sarcoma compared to the rest of histologi-
cal subtypes including those with liposarcoma and undif-
ferentiated pleomorphic sarcoma (Table 2). However, the 
small sample size of each histological subtype was insuf-
ficient to allow conclusive results.
Another salient finding from this study was the poor 
participation rate of patients with advanced STS in clini-
cal trials. Approximately 20  % of patients treated with 
chemotherapy were enrolled in clinical trials during 
their course of disease with the majority participating in 
Phase III studies as the first-line therapy. This represents 
a strikingly small number of participants in contrast to 
56–67 % of patients accessing clinical trials in European 
and North American settings [8, 9]. Australian medical 
oncologists are actively engaged in local and interna-
tional cancer clinical trials. However, the heterogeneity 
and the rarity of soft tissue sarcoma, combined with the 
relative geographical isolation of Australia pose signifi-
cant challenges in developing and opening clinical tri-
als. Enhancing clinical trial access is critical, not only to 
improve cancer outcomes, but also to empower patients 
to play an active role in their management and to gain 
access to new treatments before they become widely 
available. Recent efforts by the Australian Sarcoma Study 
Group have facilitated multiple Australian and New Zea-
land sites to participate in investigator-initiated research 
as well as internationally-led cooperative group trials 
[17]. This is an important step forward in fostering rela-
tionship with future partners for sarcoma initiatives and 
research projects.
Access to new emerging agents continues to be a 
barrier to Australian patients. A total of 15 patients 
accessed novel agents, pazopanib (n =  12) and trabect-
edin (n = 3), for various STS subtypes, via compassion-
ate access schemes. Although benefit in progression-free 
survival was not assessed in this series, these agents 
serve as additional active agents, which are important 
for patients with advanced STS. In general, timelines for 
access to new agents in Australia is lagging behind that 
of Europe and the United States. It is worth noting that 
it took seven more years for trabectedin to obtain a seal 
of approval by the Food and Drug Administration of the 
United States since its first approval in Europe in 2007. 
Trabectedin is yet to be approved by the Australian regu-
latory authority. On the other hand, pazopanib, has been 
added to the Pharmaceutical Benefits Scheme listing in 
March 2014 in Australia for the indication of non-adipo-
cytic STS and will assist patients’ access to this targeted 
option at a Government-subsidised price [18].
The median overall survival of patients in our cohort 
was 18  months, which is longer than previous studies 
reporting approximately 12  months in this setting [19, 
20]. However, long-term survival has been described in 
a subset of patients with limited disease burden and cer-
tain STS histologic subtypes are well recognised for their 
slow and indolent natural history. It is worth noting that 
the SABINE study evaluating a highly selected group of 
patients with a favourable response to chemotherapy 
reported the median overall survival as 23  months [8]. 
Interestingly, the group of patients who received pallia-
tive-intent systemic therapy in our study had the over-
all survival of only 11 months, which is more consistent 
with the historical control [19, 20]. This may represent 
the clinician’s decision in selecting patients with symp-
tomatic and larger disease burden to receive systemic 
therapy. Not surprisingly in the setting of advanced or 
metastatic disease, the cause of death in most patients 
was disease-related.
There are several strengths to our data including 
the prospective nature of comprehensive data collec-
tion from the time of diagnosis through to recurrence 
and death. Details on clinic-pathological data as well as 
treatments were complete for analysis in most patients. 
Given the intrinsic heterogeneity of STS and its rarity, a 
considerable level of complexity exists in capturing an 
accurate dataset. However, a high quality, well-main-
tained database can be utilised as an important resource 
for research, including many questions not adequately 
addressed by clinical trials. Some limitations are worth 
noting. Data on multiple STS histological subtypes were 
combined together for this analysis, as they are com-
monly done in other studies. This renders interpretation 
of results difficult in treatment uptake and survival, as 
certain histological subtypes are inherently different from 
one another.
Conclusions
In this retrospective study, we reviewed the patterns of 
care in managing patients with locally advanced and/or 
metastatic STS at sarcoma specialist services, providing 
a valuable insight into the current practice in the Aus-
tralian health care setting. The presented data highlight 
varying practice in delivering palliative-intent treatment 
modalities at different time points and the ongoing need 
for addressing lack of clinical trials for sarcoma patients 
in Australia. The study will serve as an important refer-
ence point for understanding how practice may change 
over time as treatment options continue to evolve.
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